Endocrine Pharmacology Practice Questions

Q: What is the recommended replacement dose of thyroxine?

0.1 - 0.2 mg. The correct answer is **A. 0.1 - 0.2 mg**. ### **Explanation** The goal of thyroxine (L-thyroxine) replacement therapy in hypothyroidism is to restore the patient to a euthyroid state. The standard daily maintenance dose for an average adult is approximately **1.6 µg/kg body weight**. For a typical adult weighing 60–70 kg, this calculates to roughly **100–150 µg (0.1 to 0.15 mg)** per day. Therefore, the range of **0.1 – 0.2 mg** (100–200 µg) is the clinically accepted standard for full replacement. ### **Analysis of Incorrect Options** * **B (0.3 - 0.4 mg):** This dose is excessively high for standard replacement and would likely lead to iatrogenic hyperthyroidism, increasing the risk of atrial fibrillation and osteoporosis. * **C & D (1 - 4 mg):** These doses are massive and potentially fatal. They are far beyond the physiological requirements of the human body. ### **High-Yield NEET-PG Pearls** * **Monitoring:** The best indicator for adjusting the dose in primary hypothyroidism is the **Serum TSH level**. (Target: 0.5–2.5 mIU/L). * **Administration:** Thyroxine should be taken on an **empty stomach** (30–60 minutes before breakfast) because food, calcium, and iron supplements significantly decrease its absorption. * **Special Populations:** * **Elderly/Cardiac patients:** Start with a lower dose (12.5–25 µg) to avoid precipitating angina or myocardial infarction. * **Pregnancy:** Thyroxine requirements typically **increase** by 30–50% due to increased TBG levels. * **Drug of Choice:** Levothyroxine (T4) is preferred over Liothyronine (T3) due to its longer half-life (7 days), consistent blood levels, and peripheral conversion to T3.

Q: Which of the following drugs is an alpha-glucosidase inhibitor?

Miglitol. **Explanation:** **Alpha-glucosidase inhibitors (AGIs)**, such as **Miglitol** and **Acarbose**, act locally in the small intestine. They competitively inhibit the enzyme alpha-glucosidase, which is responsible for breaking down complex carbohydrates (disaccharides and oligosaccharides) into absorbable monosaccharides like glucose. By delaying carbohydrate absorption, these drugs primarily reduce **post-prandial hyperglycemia**. **Analysis of Options:** * **Miglitol (Correct):** It is a potent AGI. Unlike Acarbose, Miglitol is almost completely absorbed from the gut but is not metabolized and is excreted unchanged by the kidneys. * **Pioglitazone (Incorrect):** Belongs to the **Thiazolidinedione (TZD)** class. It acts as a PPAR-gamma agonist, increasing peripheral insulin sensitivity (primarily in adipose tissue and muscle). * **Metformin (Incorrect):** A **Biguanide** and the first-line drug for Type 2 Diabetes. Its primary mechanism is the activation of AMP-activated protein kinase (AMPK), which suppresses hepatic gluconeogenesis. * **Nateglinide (Incorrect):** A **Meglitinide analogue** (Glinide). It acts as a short-acting insulin secretagogue by closing ATP-sensitive K+ channels in pancreatic beta cells. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effects of AGIs are GI-related: flatulence, bloating, and diarrhea (due to fermentation of undigested carbohydrates in the colon). * **Hypoglycemia Management:** If a patient on an AGI experiences hypoglycemia (usually due to concurrent sulfonylurea use), they must be treated with **pure glucose (dextrose)**, not sucrose (cane sugar), because AGIs block the breakdown of sucrose. * **Weight Neutrality:** AGIs are generally weight-neutral and do not cause hypoglycemia when used as monotherapy.

Q: Hydrocortisone acts as an anti-inflammatory agent because of the induction of the synthesis of which of the following proteins?

Annexin A1. **Explanation:** The anti-inflammatory action of glucocorticoids like **Hydrocortisone** is primarily mediated through the regulation of gene expression. When hydrocortisone binds to its intracellular glucocorticoid receptor (GR), the complex translocates to the nucleus and induces the transcription of specific anti-inflammatory proteins. **Annexin A1 (also known as Lipocortin-1)** is the most significant of these induced proteins. Its primary mechanism is the **inhibition of Phospholipase A2 (PLA2)**. By inhibiting PLA2, Annexin A1 prevents the release of arachidonic acid from the cell membrane, thereby blocking the synthesis of both prostaglandins (via the COX pathway) and leukotrienes (via the LOX pathway). This dual inhibition is what makes steroids more potent anti-inflammatory agents than NSAIDs. **Analysis of Incorrect Options:** * **A. Heat shock protein 90 (hsp90):** This protein acts as a "chaperone" that keeps the glucocorticoid receptor in an inactive state in the cytoplasm. Hydrocortisone causes the *release* of hsp90, not its synthesis. * **B. Inhibin:** This is a peptide hormone produced by the gonads to inhibit FSH secretion; it has no role in the mechanism of corticosteroids. * **C. Transcortin:** Also known as Corticosteroid Binding Globulin (CBG), this is the transport protein for cortisol in the blood. It is synthesized in the liver, not induced by hydrocortisone as part of its anti-inflammatory effect. **High-Yield Clinical Pearls for NEET-PG:** * **Genomic vs. Non-genomic:** Annexin A1 induction is a **genomic effect** (takes time). * **NF-κB Inhibition:** Glucocorticoids also suppress inflammation by inhibiting the transcription factor NF-κB, which reduces the production of pro-inflammatory cytokines (IL-1, TNF-α). * **Metabolic Side Effects:** Remember that while they suppress inflammation, they induce enzymes for gluconeogenesis, leading to hyperglycemia (Steroid Diabetes).

Q: Growth Hormone may be beneficial in which of the following conditions, except?

Laron type dwarfism.. ### Explanation **1. Why Laron Type Dwarfism is the Correct Answer:** Laron dwarfism is characterized by **Growth Hormone (GH) receptor insensitivity**. In this condition, GH levels are actually normal or elevated, but the receptors are non-functional, leading to a failure in the production of **IGF-1 (Insulin-like Growth Factor-1)**. Since the defect lies at the receptor level, administering exogenous Growth Hormone will have no effect. The treatment of choice for Laron dwarfism is **Mecasermin** (recombinant IGF-1). **2. Analysis of Incorrect Options:** * **Constitutional Growth Delay:** GH can be used to increase final adult height in children who are significantly below the growth curve, even if they are not GH deficient. * **Osteoporosis:** GH stimulates osteoblast activity and increases bone mineral density. While not a first-line treatment, it is physiologically beneficial and approved for use in GH-deficient adults with low bone mass. * **Panhypopituitarism:** This involves a deficiency of all anterior pituitary hormones, including GH. Replacement therapy with recombinant GH (Somatropin) is a standard indication to restore normal growth and metabolic function. **3. High-Yield Clinical Pearls for NEET-PG:** * **Somatropin:** Recombinant human GH used for GH deficiency, Turner syndrome, Prader-Willi syndrome, and Chronic Renal Failure. * **Somatomedin C:** Another name for IGF-1; it mediates most of the growth-promoting effects of GH. * **Side Effects of GH:** Slipped capital femoral epiphysis, pseudotumor cerebri, and hyperglycemia (diabetogenic potential). * **Contraindication:** GH should not be used in patients with active malignancy or closed epiphyses.

Q: All of the following are true regarding the use of iodine, except:

Its use is contraindicated in hyperthyroidism.. **Explanation:** The correct answer is **D**, as iodine is **not** contraindicated in hyperthyroidism; rather, it is used strategically in specific clinical scenarios. **1. Why Option D is the correct answer (The Exception):** Iodine (usually as Lugol’s iodine or potassium iodide) is a standard treatment for hyperthyroidism in two specific cases: **Pre-operative preparation** for thyroidectomy (to decrease the vascularity and size of the gland) and **Thyroid Storm** (to rapidly block hormone release). Therefore, stating it is contraindicated is medically incorrect. **2. Analysis of other options:** * **Option A (True):** High doses of iodine acutely inhibit the proteolysis of thyroglobulin, thereby blocking the **release** of T3 and T4 into the circulation. This is the fastest-acting mechanism to lower thyroid levels. * **Option B (True):** This refers to the **Wolff-Chaikoff effect**, where high plasma iodide concentrations cause a transient inhibition of the organic binding of iodine (organification), stopping the synthesis of iodotyrosine and iodothyronine. * **Option C (True):** **Iodism** is a chronic toxicity resulting from iodine use. Symptoms include a metallic taste, burning sensation in the mouth, sneezing (coryza), and swelling of the eyelids/salivary glands. **Clinical Pearls for NEET-PG:** * **The Escape Phenomenon:** The Wolff-Chaikoff effect is transient; the thyroid "escapes" this inhibition after 10–14 days. Thus, iodine should not be used as long-term monotherapy. * **Jod-Basedow Phenomenon:** In contrast to the Wolff-Chaikoff effect, iodine administration in a deficient patient can sometimes *induce* hyperthyroidism. * **Amiodarone:** This antiarrhythmic drug contains high iodine content and can cause both hyper- and hypothyroidism.

Q: Which dopamine agonist is used in the management of diabetes mellitus?

Bromocriptine. **Explanation:** **Bromocriptine** is a potent dopamine D2 receptor agonist. While primarily known for treating hyperprolactinemia and Parkinson’s disease, a specific quick-release (QR) formulation of Bromocriptine is FDA-approved for the management of **Type 2 Diabetes Mellitus**. **Mechanism of Action:** In patients with Type 2 DM, there is often a decrease in dopaminergic tone in the hypothalamus during the morning. Bromocriptine QR, when administered within two hours of waking, acts on the circadian rhythm to increase hypothalamic dopaminergic activity. This results in a reduction of sympathetic outflow, leading to decreased hepatic glucose production (gluconeogenesis), reduced insulin resistance, and lower free fatty acid levels without increasing insulin secretion. **Analysis of Incorrect Options:** * **A. Metformin:** This is a Biguanide, not a dopamine agonist. It is the first-line drug for Type 2 DM, acting primarily by activating AMPK to inhibit hepatic gluconeogenesis. * **C. Cabergoline:** Although it is a long-acting dopamine agonist used for prolactinomas, it is **not** approved or used for the management of glycemic control in diabetes. * **D. Vanadium salts:** These are trace elements that have "insulin-mimetic" properties but are not dopamine agonists and are not used in standard clinical practice due to toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Bromocriptine QR** is the only dopamine agonist approved for DM. * It does **not** cause hypoglycemia or weight gain, making it unique among many oral hypoglycemics. * It is also known to reduce the risk of major adverse cardiovascular events (MACE). * **Side effects:** Nausea, dizziness, and orthostatic hypotension are common during initiation.

Q: Which of the sulfonylureas is the best choice in patients with chronic kidney disease?

Glipizide. **Explanation:** The primary concern when using sulfonylureas in patients with chronic kidney disease (CKD) is the risk of **severe, prolonged hypoglycemia**. This occurs because many sulfonylureas or their active metabolites are excreted renally. [1] **Why Glipizide is the Correct Choice:** Glipizide is considered the safest sulfonylurea in CKD because it is primarily metabolized by the **liver** into **inactive metabolites**. These inactive metabolites are then excreted in the urine, posing no risk of hypoglycemia even if they accumulate due to a low Glomerular Filtration Rate (GFR). It also has a shorter half-life compared to other agents in its class. **Analysis of Incorrect Options:** * **Glibenclamide (Glyburide):** These are the same drug (Option B and D). It is **contraindicated** in CKD (especially if GFR <60 mL/min). It has active metabolites that are cleared by the kidneys; accumulation leads to profound, life-threatening hypoglycemia. * **Glimepiride:** While it is a second/third-generation agent, it possesses active metabolites that are renally cleared. It should be used with extreme caution or avoided in advanced CKD. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** While Glipizide is the best *sulfonylurea* for CKD, the overall oral hypoglycemic agent of choice in advanced CKD is typically a **DPP-4 inhibitor** (like Linagliptin, which requires no renal adjustment) or **Insulin**. [2] * **Metformin:** Must be discontinued if **eGFR <30 mL/min** due to the risk of lactic acidosis. [1] * **Gliclazide:** Another preferred sulfonylurea in mild-to-moderate CKD as it has inactive metabolites, but Glipizide remains the classic textbook answer for safety. * **Rule of Thumb:** "Glipizide stays in the liver, Glyburide gets stuck in the kidney."

Q: Which of the following is an anti-progesterone drug?

Mifepristone. **Explanation:** **Mifepristone (RU-486)** is the correct answer because it is a potent **competitive progesterone receptor antagonist**. It binds to progesterone receptors with higher affinity than endogenous progesterone, preventing the hormone from maintaining the decidua. This leads to the detachment of the blastocyst and sensitization of the uterus to prostaglandins. **Analysis of Incorrect Options:** * **Cyproterone:** This is an **anti-androgen** (androgen receptor antagonist) with weak progestational activity. It is used in the management of hirsutism, acne, and precocious puberty. * **Spironolactone:** Primarily a potassium-sparing diuretic, it also acts as an **aldosterone antagonist** and has significant anti-androgenic properties. It is not an anti-progestin. * **Tamoxifen:** This is a **Selective Estrogen Receptor Modulator (SERM)**. It acts as an antagonist in the breast (used in breast cancer) but as an agonist in the bone and endometrium. **High-Yield Clinical Pearls for NEET-PG:** * **Medical Abortion Regimen:** Mifepristone (200 mg orally) is followed 36–48 hours later by **Misoprostol** (400–800 mcg) to induce uterine contractions. This is effective up to 7-9 weeks of gestation. * **Cushing’s Syndrome:** Mifepristone is also FDA-approved for controlling hyperglycemia in patients with endogenous Cushing’s syndrome (due to its **glucocorticoid receptor antagonism** at high doses). * **Emergency Contraception:** Mifepristone can be used as a single dose for emergency contraception (though Levonorgestrel and Ulipristal are more common). * **Ulipristal:** Another important Selective Progesterone Receptor Modulator (SPRM) used for emergency contraception and uterine fibroids.

Question 1

What is the recommended replacement dose of thyroxine?

Accepted Answer

0.1 - 0.2 mg

Answer

0.3 - 0.4 mg

Answer

1 - 2 mg

Answer

3 - 4 mg

Question 2

Which of the following drugs is an alpha-glucosidase inhibitor?

Accepted Answer

Miglitol

Answer

Pioglitazone

Answer

Metformin

Answer

Nateglinide

Question 3

Hydrocortisone acts as an anti-inflammatory agent because of the induction of the synthesis of which of the following proteins?

Accepted Answer

Annexin A1

Answer

Heat shock protein 90

Answer

Inhibin

Answer

Transcortin

Question 4

What is the most important side effect of insulin?

Accepted Answer

Hypoglycaemia

Answer

Lipodystrophy

Answer

Insulin resistance

Answer

Antibodies to insulin

Question 5

Growth Hormone may be beneficial in which of the following conditions, except?

Accepted Answer

Laron type dwarfism.

Answer

In children with constitutional growth delay.

Answer

In treatment of osteoporosis.

Answer

Panhypopituitarism.

Question 6

All of the following are true regarding the use of iodine, except:

Accepted Answer

Its use is contraindicated in hyperthyroidism.

Answer

It inhibits the release of thyroid hormones.

Answer

It causes acute inhibition of iodotyrosine and iodothyronine synthesis.

Answer

It can cause iodism.

Question 7

Which dopamine agonist is used in the management of diabetes mellitus?

Accepted Answer

Bromocriptine

Answer

Metformin

Answer

Cabergoline

Answer

Vanadium salts

Question 8

Which of the sulfonylureas is the best choice in patients with chronic kidney disease?

Accepted Answer

Glipizide

Answer

Glimipride

Answer

Glibenclamide

Answer

Glyburide

Question 9

Which of the following is an anti-progesterone drug?

Accepted Answer

Mifepristone

Answer

Cyproterone

Answer

Spironolactone

Answer

Tamoxifen

Question 10

Which of the following statements regarding finasteride is FALSE?

Accepted Answer

It blocks the conversion of testosterone to dihydrotestosterone.

Answer

It is used in the treatment of benign prostatic hyperplasia.

Answer

Impotence is well-documented after its use.

Answer

It is a 5-alpha reductase inhibitor.

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?